Significance of ectodomain shedding of TNF receptor 1 in ocular surface

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 4, 2014, Pages 2419-2423

  Sakimoto, Tohru ^a   Ohnishi, Takako ^a   Ishimori, Akiko ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytokine receptor; Ectodomain shedding; TNF receptor

Indexed keywords

CYTOKINE RECEPTOR; ECTODOMAIN SHEDDING; TNF RECEPTOR;

BLOTTING, WESTERN; CELLS, CULTURED; DRY EYE SYNDROMES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIUM, CORNEAL; HUMANS; OPHTHALMIC SOLUTIONS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TEARS;

EID: 84898839844     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13265     Document Type: Article

References (27)

1. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10:45-65.
2. Cabal-Hierro L, Lazo PS. Signal transduction by tumor necrosis factor receptors. Cell Signal. 2012;24:1297-1305.
3. 2+ determines the severity of inflammation in mouse lung microvessels. J Clin Invest. 2011;121:1986-1999.
4. Kneilling M, Mailhammer R, Hültner L, et al. Direct crosstalk between mast cell-TNF and TNFR1-expressing endothelia mediates local tissue inflammation. Blood. 2009;114:1696-1706.
5. Xanthoulea S, Pasparakis M, Kousteni S, et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J Exp Med. 2004;200: 367-376.
6. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A. 1992;89:4845-4849.
7. Sakimoto T, Yamada A, Sawa M. Release of soluble tumor necrosis factor receptor 1 from corneal epithelium by TNFalpha-converting enzyme-dependent ectodomain shedding. Invest Ophthalmol Vis Sci. 2009;50:4618-4621.
8. Sakimoto T, Sawa M. Metalloproteinases in corneal diseases: degradation and processing. Cornea. 2012;31(suppl 1):S50-S56.
9. Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a twenty-five-year review. Cornea. 2000;19:644-649.
10. Yoon KC, Jeong IY, Park YG, Yang SY. Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea. 2007;26:431-437.
11. Massingale ML, Li X, Vallabhajosyula M, Chen D, Wei Y, Asbell PA. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea. 2009;28:1023-1027.
12. Na KS, Mok JW, Kim JY, Rho CR, Joo CK. Correlations between tear cytokines, chemokines, and soluble receptors and clinical severity of dry eye disease. Invest Ophthalmol Vis Sci. 2012; 53:5443-5450.
13. Riemens A, Stoyanova E, Rothova A, Kuiper J. Cytokines in tear fluid of patients with ocular graft-versus-host disease after allogeneic stem cell transplantation. Mol Vis. 2012;18:797-802.
14. Wang Y, Ogawa Y, Dogru M, et al. Baseline profiles of ocular surface and tear dynamics after allogeneic hematopoietic stem cell transplantation in patients with or without chronic GVHDrelated dry eye. Bone Marrow Transplant. 2010;45:1077-1083.
15. Sugaya S, Sakimoto T, Shoji J, Sawa M. Regulation of soluble interleukin-6 (IL-6) receptor release from corneal epithelial cells and its role in the ocular surface. Jpn J Ophthalmol. 2011;55:277-282.
16. Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K. Diquafosol Ophthalmic Solution Phase 2 Study Group. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial. Ophthalmology. 2012;119:1954-1960.
17. Shimazaki-Den S, Iseda H, Dogru M, Shimazaki J. Effects of diquafosol sodium eye drops on tear film stability in short BUT type of dry eye. Cornea. 2013;32:1120-1125.
18. Parsons PE, Matthay MA, Ware LB, et al. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2005;288:L426-L431.
19. Nilsson L, Szymanowski A, Swahn E, Jonasson L. Soluble TNF receptors are associated with infarct size and ventricular dysfunction in ST-elevation myocardial infarction. PLoS One. 2013;8:e55477.
20. Gohda T, Tomino Y. Novel biomarkers for the progression of diabetic nephropathy: soluble TNF receptors. Curr Diab Rep. 2013;13:560-566.
21. Paczesny S, Krijanovski OI, Braun TM, et al. A biomarker panel for acute graft-versus-host disease. Blood. 2009;113:273-278.
22. Cantarini L, Lucherini OM, Muscari I, et al. Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev. 2012;12:38-43.
23. Saftig P, Reiss K. The "A Disintegrin And Metalloproteases" ADAM10 and ADAM17: novel drug targets with therapeutic potential? Eur J Cell Biol. 2011;90:527-535.
24. Nakamura M, Imanaka T, Sakamoto A. Diquafosol ophthalmic solution for dry eye treatment. Adv Ther. 2012;29:579-589.
25. Choy EH, Kavanaugh AF, Jones SA. The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol. 2013;9:154-163.
26. Caorsi R, Federici S, Gattorno M. Biologic drugs in autoinflammatory syndromes. Autoimmun Rev. 2012;12:81-86.
27. Horneff G. Update on biologicals for treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther. 2013;13:361-376.